– USA, MA – Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Susannah Gray to its Board of Directors.
Ms. Gray is an accomplished leader in healthcare finance and serves as a director on the boards of multiple healthcare companies. Ms. Gray was most recently EVP, finance, and strategy at Royalty Pharma.
“Susannah Gray brings a broad range of senior healthcare finance strategy experience to Morphic, with notable accomplishments in capital formation, strategy and corporate governance,” said Board Chairman, Gustav Christensen. “I and the entire Morphic team welcome Susannah and we look forward to her contributions as Morphic continues to advance its portfolio of integrin-targeted oral therapeutics.”
Simultaneously, Dr. Otello Stampacchia has stepped down from the Board of Directors.
Dr. Praveen Tipirneni, president and CEO commented: “On behalf of Gustav and the Morphic Board, I want to thank Otello for his counsel and many contributions to Morphic’s growth as it has matured from a preclinical organization based on an ambitious technology to the promising clinical company that we have become.”
Further, Vikas Goyal has determined that he will not stand for re-election to the Morphic Board of Directors when his current term expires.
“We thank Vikas deeply for his early recognition of the potential to create oral integrin medicines through the MInT platform and his steadfast support of the Morphic team. I also congratulate him on his recent successes at Pandion and look forward to collaborating again in the future,” said Dr. Praveen Tipirneni.
About Susannah Gray
Susannah Gray is a veteran leader in healthcare finance and strategy with three decades of experience in capital formation, operational management, healthcare asset monetization, investment research, and strategy implementation. Ms. Gray is a member of the board of directors of corporate and non-profit institutions including Morphic Therapeutic, 4D Molecular Therapeutics, Maravai Life Sciences, Wesleyan University, Susan G. Komen Foundation, and StreetSquash.
Susannah Gray was executive vice president and chief financial officer at Royalty Pharma from 2005-2019. Before Royalty Pharma, she served as managing director of fixed income research at CIBC World Markets and held positions of increasing leadership at Chase Securities and Merrill Lynch.
”Morphic Therapeutic has the rare combination of an innovative drug discovery platform coupled with the human and financial resources to create innovative therapies,” commented Susannah Gray. “ I look forward to working with the Morphic team as they advance MORF-057 in clinical development and continue to generate oral integrin drug candidates based on the MInT Platform.”
Susannah Gray holds a BA from Wesleyan University and an MBA from Columbia University Business School.
About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT platform which leverages the Company’s unique understanding of integrin structure and biology.
For more information: https://morphictx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.